Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Follow her on Twitter @megtirrell.
Theranos ends the year on thin ice financially, CNBC's Meg Tirrell reports.
CNBC's Leslie Picker reports on David Tepper's Allergan bet as he ups the stake by 250%. With CNBC's Meg Tirrell.
CNBC's Meg Tirrell speaks with John Cox, Bioverativ CEO, about the company's spinoff from Biogen, its new innovations in treating hemophilia.
Earnings are out for Express Scripts. CNBC's Meg Tirrell reports the details.
CNBC's Meg Tirrell reports the latest on how the fight over drug prices has sparked a civil war in the pharmaceutical industry, with big branded companies in one corner and the generics in the other.
Marathon Pharmaceuticals delays the launch of their $89,000 muscular dystrophy drug amid drug pricing concerns. CNBC's Meg Tirrell reports.
Marathon says it will charge $89,000 for its Duchenne muscular dystrophy treatment, despite it having sold elsewhere for just $1,000.
Congress targets Marathon Pharmaceuticals over the company's high drug prices. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell reports on Gilead's new drug that cures Hepatitis C.